Melasma poses a great challenge as its treatment is unsatisfactory and recurrence is high. Treatment of melasma using tranexamic acid (oral, topical or intralesional) is a novel concept.
INTRODUCTION
Melasma/cholasma manifests as symmetrical and irregular tan-brown macules on the face. 1 Though predominantly seen on the malar areas of cheek, it may also appear on forehead and chin. Exposure to ultraviolet (UV) radiation, genetic susceptibility and hormonal imbalance are considered to be its etiological factors. Although no race is spared, melasma is far more common in women and in dark skinned individuals. 2 It is a common and growing cosmetic concern among Nepalese population with Fitzpatrick skin types III-V. 3 Till date none of its existing treatment modalities has provided quick and sustained result. Today topical hydroquinone is considered to be the gold standard among topical treatments of melasma. 4 Prevention of UV radiation, topical bleaching agents, chemical peel and light based therapies are the currently existing plethora of remedies. Addition of Tranaxemic Acid (TXA) for the treatment of melasma is a novel concept. Previously used as an antifibrinolytic agent, TXA is recently found to inhibit plasminogen-keratinocyte interaction decreasing the tyrosinase activity causing decreased melanin synthesis from the melanocytes. 5, 6 Very few clinical trials have been conducted regarding the efficacy of TXA (oral, topical or intralesional) for the treatment of melasma. This study is thus conducted to compare the efficacy of oral TXA along with routine treatment measures for the treatment of melasma.
METHODS
It is a prospective, interventional, randomized controlled trial conducted among 260 (217 female and 43 male) melasma patients. The sample size was calculated at 236 taking prevalence of 10% in Nepalese population with confidence level at 95% and margin of error at 0.05. 16 This study was conducted in the Department of Dermatology, Dhulikhel Hospital, Dhulikhel, Nepal from June 2011 to June 2012, after taking consent from the institutional review committee. Age of patients ranged from 17-55 years (mean age 30.3 ± 9.01 years). All patients were checked for bleeding time, clotting time, platelet count before they were included in the study. Patients with abnormal parameters were not included in the study. The type of melasma was graded with Wood's lamp and dermatoscopic examination. Patients were randomly divided into two groups consisting of 130 patients each using random number table. First group (Group A) was added on with oral TXA along with routine topical treatment measures while second group (Group B) was treated only with routine topical measures. Topical treatment included topical hydroquinone and sunscreen according to the skin types. Capsule tranexamic acid (Trancap®) was prescribed at a dose of 250 mg twice a day for three months and cases were followed up four weekly till the end of third month. Patients who discontinued the treatment or wanted chemical peel or laser for better response were excluded from the study. Response was evaluated on the basis of Melasma Assessment Severity Index (MASI) score. 7 MASI score was calculated during the start of therapy (baseline) and at the end of eight and twelve weeks.
MASI is a scoring system introduced by Kimbrough-Green CK et. al. used to quantify the severity of melasma. 7 Four areas of the face are evaluated: forehead (F), right malar region (MR), left malar region (ML) and chin(C), corresponding to 30%, 30%, 30%, and 10% of the total face respectively. Amount of pigmentation involved by melasma in these four areas (AF, AMR, AML, and AC) is graded as a numerical value: 0: no involvement; 1: less than 10% involvement; 2: 10-29%; 3: 30-49%; 4: 50-69%; 5: 70-89%; and 6: 90-100%. Severity of melasma is graded upon two factors; darkness (D) of melasma compared to the normal skin and homogeneity (H) of hyperpigmentation. These are assessed on a scale from 0 to 4. The rating scale for both darkness and homogeneity of melasma is as follows; 0: absent; 1: slight; 2: mild; 3: marked; and 4: maximum. MASI score is then calculated according to the following formula: The maximum score for MASI can be 48 while minimum can be 0. SPSS ver 16 was used for the statistical analysis. Mean MASI scores were compared with students' T-test and statistical significance was compared. Patient satisfaction score was subjectively graded on the basis of four point Likert scale: excellent, good, fair, and poor. Possible side effects of TXA were noted on follow up of patients. The demographical variables, type and distribution of melasma is shown in table 1. Patients rating for good to excellent outcome accounted 82.3% and 40.8% among group A and group B patients respectively. (Fig. 1,2) .
RESULTS
Among group A patients, statistically significant decrease in the mean MASI score was observed from baseline at eight and twelve weeks (11.08±2.91 vs 8.95±2.08 at week 8 and vs. 7.84±2.44 at week 12; p<0.05 for both). While among group B patients the decrease in mean score was significant at eight weeks and insignificant at twelve weeks follow up (11.60±3.40 vs 9.9±2.61 at eight weeks and vs. 9.26±3 at 12 weeks; p<0.05 for former but p>0.05 for later). Fig 3 and 4 shows photograph of a patient of group a before and after the treatment.
Oral TXA was found to be relatively safe. Certain side effects seen among group A patients were oligomenorrhea (14.7% ladies), belching (9.2%), abdominal cramps (6.9%), palpitation and urticarial rash with angioedema (in one patient each). No serious systemic complication was observed during the study period.
Two patients treated for hydroquinone induced exogenous ochronosis with TXA, topical retinoids and non hydroquinone bleaching agent were found to have significant improvement at the end of 12 weeks follow. Our experience also showed that response of epidermal melasma was quicker and better than compared to dermal or mixed variant. Further, some patients of group A excluded from the study during middle of the treatment were simultaneously treated with ablative fractional Erb:
YAG laser and were found to have better and quicker response in dermal or mixed type of melasma.
DISCUSSION
Pathologically increased epidermal melanogenesis following a triggering factor results in melasma. 1 Measurement of endocrine parameters have shown elevated levels of luteinizing hormone and decreased levels of oestradiol, suggesting subclinical mild ovarian dysfunction. 2 The major target of its treatment thus remains to decrease the melanin synthesis, remove the excess melanin or use of bleaching agents and avoidance of any etiological agent. Treatment of melasma is a challenge because of its multifactorial etiology. Topical treatments may temporarily result in improvement, but the condition often returns.
Clinical trials have shown that topical medications demonstrate some efficacy in the epidermal type but not in dermal or mixed type of melasma. 8, 9 Prolonged application, slow response, limited effects and undesirable recurrence are the major disadvantages of topical therapies causing patients to abandon the treatment. Also, topical bleaching agents may irritate the skin and develop postinflammatory hyperpigmentation or result in exogenous ochronosis. Laser assisted treatment is a good method however recurrence remains disappointing. 10 The most effective and safe treatment for melasma is thus yet to be explored.
Tranexamic acid (trans-4-aminomethyl cyclohexane Original Article carboxylic acid) is used as a haemostatic agent due to its antifibrolytic action. 11 It is a synthetic derivative of the amino acid lysine used to treat and prevent excessive bleeding. Nijor first studied and reported the action of TXA on melasma in 1979. 12 However, limited studies are found in the literature regarding the use of TXA on melasma. Maeda K et. al. studied the role of TXA in human melanocyte and keratinocyte cultures. 11, 12 Their results revealed that TXA inhibits melanin synthesis in epidermal melanocytes' tyrosinase activity by blocking the interaction of melanocytes and keratinocytes by inhibition of plasminogen/plasmin system. TXA acts by attaching to the lysine-binding sites of plasmin and plasminogen and also prevents ultraviolet rays induced pigmentation.
Similar study as ours was conducted on a split-face based trial with topical TXA gel. 13 Their results showed lightening of pigmentation but was insignificant in comparison to the control group. Also topical TXA produced erythema. Lee JH et al. injected localized intradermal microinjection of TXA for Melasma and found statistically significant lightening. 9 Histological evaluation following oral and topical TXA for melasma was done which concluded that TXA decreases epidermal pigmentation associated with melasma and also reverses melasma-related dermal changes, such as vessel number and increased numbers of mast cells.
14 Use of oral TXA for melasma in similar dose have been tried in Chinese population and authors recommend TXA to be an effective and safe therapy for the treatment of melasma. 15 Dose of oral TXA used in melasma is far less than that prescribed for its haemostatic action. Venous thromboembolism, myocardial infarction, cerebrovascular accidents and pulmonary embolism are some reported complications in haemostatic dose of TXA. It is contraindicated for patients having acquired defective color vision, an active intravascular clotting condition, and hypersensitivity to TXA. Hence, proper patient selection ruling out any risk factor resulting in hypercoagulability is of pivotal importance prior to the start of therapy.
Our results correspond with the related studies where successful lightening was observed following oral TXA administration. Despite the lack of an objective measurement in the improvement, we observed good clinical outcome of melasma. Further, longer duration follow up and randomized controlled trials involving larger number of patients are demanded for further exploration of efficacy of TXA in the near future. Oral TXA being a non invasive, nonirritating drug with low side effect profile we routinely recommend the use of low dose oral TXA in patients with melasma.
The study is done in a single center over a period of one year. A much larger multicenter study is necessary to validate the study.
